This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS . Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265–276.
Molica S . Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma 2006; 47: 1477–1480.
Cartwright RA, Gurney KA, Moorman AV . Sex ratios and the risks of haematological malignancies. Br J Haematol 2002; 118: 1071–1077.
Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184.
Ghiotto F, Fais F, Valetto A, Albesiano E, Hashimoto S, Dono M et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004; 113: 1008–1016.
Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007; 109: 259–270.
Catera R, Hatzi K, Chu CC, Herve M, Meffre E, Ferrarini M et al. Polyreactive monoclonal antibodies synthesized by some B-CLL cells recognize specific antigens on viable and apoptotic T Cells. Blood 2006; 108: 2813.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by grants from the Medical Research Council, from the Hope Foundation and the Leukaemia Research Fund.
Rights and permissions
About this article
Cite this article
Walewska, R., Majid, A., Davis, Z. et al. Male preponderance in chronic lymphocytic leukemia utilizing IGHV 1–69. Leukemia 21, 2537–2538 (2007). https://doi.org/10.1038/sj.leu.2404836
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404836